For Immediate Release
Media Contact: Bob Cooper
Date: October 12, 2006
Wasden Delivers $154,718 to Idaho Comprehensive Cancer Control Program
(Boise) – Attorney General Lawrence Wasden presented the Idaho Comprehensive Cancer Control Program a check for $154,718 from a settlement earlier this year with TAP Pharmaceutical Products, Inc., the manufacturer of the prescription drug Lupron. The Attorney General’s Office previously distributed more than $33,380 to Idaho consumers who purchased Lupron.
“The Idaho Comprehensive Cancer Control Program’s mission is to develop a statewide strategic cancer control program for Idaho,” Attorney General Wasden said. “I hope this money will help with that mission and assist in the fight against all forms of cancer.”
The State of Idaho reached the settlement agreement involving Lupron in May. Lupron is used to treat prostate cancer, endometriosis, and early puberty. The settlement with manufacturer TAP Pharmaceutical Products, Inc., resolved potential claims regarding the pricing of the drug and did not involve the safety of the drug.
As part of the settlement, the Attorney General’s Office received $9,900 as reimbursement for the Attorney General’s costs.
- End -